Compare CVM & MYND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVM | MYND |
|---|---|---|
| Founded | 1983 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Consumer Services |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.4M | 18.3M |
| IPO Year | 1996 | 2017 |
| Metric | CVM | MYND |
|---|---|---|
| Price | $1.16 | $0.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 400.9K | 19.9K |
| Earning Date | 05-13-2026 | 05-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $264,033.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 65.45 | N/A |
| 52 Week Low | $0.89 | $0.28 |
| 52 Week High | $13.48 | $1.15 |
| Indicator | CVM | MYND |
|---|---|---|
| Relative Strength Index (RSI) | 43.10 | 49.38 |
| Support Level | $0.95 | $0.30 |
| Resistance Level | $1.52 | $0.44 |
| Average True Range (ATR) | 0.14 | 0.04 |
| MACD | 0.02 | -0.00 |
| Stochastic Oscillator | 27.90 | 49.17 |
CEL-SCI Corp is a late clinical-stage biotechnology company dedicated to research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body's natural defense system. The company is focused on the development of the following product candidates and technologies: 1) Multikine, an investigational Phase 3 immunotherapy under development for the potential treatment of certain head and neck cancers; 2) LEAPS (Ligand Epitope Antigen Presentation System) technology, for the potential treatment of rheumatoid arthritis.
Mynd.ai Inc provides world'wide, end-to-end, learning solutions and collaboration tools to help teachers, schools, students, and professionals realize their greatest potential. The company has single reporting segment. The company has presence in United States and Rest of world. The company generates majority of revenue from United States.